353 related articles for article (PubMed ID: 37686185)
1. Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents.
Su J; Luo Y; Hu S; Tang L; Ouyang S
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686185
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
3. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
4. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
6. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
Freeman JS
Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
[TBL] [Abstract][Full Text] [Related]
7. Glycaemic Control in Diabetes.
Müller-Wieland D; Brandts J; Verket M; Marx N; Schütt K
Handb Exp Pharmacol; 2022; 270():47-71. PubMed ID: 34467427
[TBL] [Abstract][Full Text] [Related]
8. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
9. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
11. Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel.
Popovic DS; Papanas N; Koufakis T; Kotsa K; Mahmeed WA; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh SY; Janez A; Kalra S; Kempler P; Kapoor N; Lessan N; Lotufo P; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Exp Clin Endocrinol Diabetes; 2023 May; 131(5):260-267. PubMed ID: 36693416
[TBL] [Abstract][Full Text] [Related]
12. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
13. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
Maccari R; Ottanà R
J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of diabetes: therapies for type 2 diabetes.
Tsoutsouki J; Wunna W; Chowdhury A; Chowdhury TA
Postgrad Med J; 2020 Oct; 96(1140):610-618. PubMed ID: 32467106
[TBL] [Abstract][Full Text] [Related]
16. The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus.
Hinnen D
J Cardiovasc Nurs; 2013; 28(2):157-65. PubMed ID: 22343215
[TBL] [Abstract][Full Text] [Related]
17. [New therapeutic developments in the treatment of type 2 diabetes mellitus].
Hintze SC; Terkamp C
Dtsch Med Wochenschr; 2022 Apr; 147(10):626-636. PubMed ID: 35545072
[TBL] [Abstract][Full Text] [Related]
18. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
19. [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus].
Gorgojo-Martínez JJ
Hipertens Riesgo Vasc; 2019; 36(3):145-161. PubMed ID: 31079957
[TBL] [Abstract][Full Text] [Related]
20. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]